CSL’s Global Role in Battling COVID-19

  • CSL Behring is part of an unprecedented industry alliance to develop a potential plasma-derived therapy for treating COVID-19. The alliance will work toward developing one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals at high risk of COVID-19, and to support national governments in their efforts to fight the current pandemic. The collaboration will leverage leading-edge expertise and work that the companies already have underway. Click here f
  • /Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.